The invention relates generally to organ perfusion. In various illustrated embodiments the invention provides for systems, methods, compositions and solutions for perfusing an organ.
Many patients need organ transplants but are unable to obtain suitable organs. One of the primary reasons is that organs that are otherwise viable when harvested from a donor are not preserved for long enough periods of time to allow them to be transported to appropriate recipients. With current preservation techniques, transplantable organs remain viable for about three to four hours and, beyond that time, suffer ischemia and tissue injury, which renders them unviable for transplant.
Current preservation techniques include cryopreservative methods, which involve the cooling of the transplantable organ to temperatures well below physiological temperatures (e.g., below 25° C.). Such techniques typically use preservation solutions that do not replenish energy sources within the organ during transplant or maintain the organ in a functioning state and therefore are largely ineffective in preventing ischemia and other injuries to the organ. The solutions also often rely on the use of high molecular weight impermeants to maintain the organ at these temperatures prior to transplantation, and such components are in many cases harmful to the organ.
Although improvements to solutions have been made over the last several years, particularly as disclosed in U.S. Pat. Nos. 6,100,082, 6,046,046, and PCT application PCT/US98/19912, further improvements are still needed.
The invention addresses deficiencies in the art by providing, in various embodiments, improved systems, methods, compositions and solutions for perfusing an organ prior to transplantation. According to one aspect, the solutions include components adapted to preserving and maintaining a harvested organ ex-vivo in its functioning state under physiologic or near physiologic conditions prior to its transplantation, while minimizing reperfusion injury and ischemia to the organ while awaiting transplantation.
According to another feature, the solutions include energy sources for the organ while it is being prepared for and undergoing transplantation. Energy sources include, for example, one or more of carbohydrate sources, components for synthesis of energy-rich molecules, such as phosphate sources, and other components. According to one embodiment, the solutions provide for amino acids for assisting the organ in cellular protein synthesis during perfusion. According to one embodiment, the solutions also provide components that help maintain the organ's normal functionality during perfusion, such as cardio stimulants, insulin and other hormones, electrolytes, etc. The solutions may also be adapted to include drugs or other therapeutics for preservation of the organ and/or patient care.
In another aspect, the invention provides for systems and methods for improved delivery of preservation. In certain embodiments the solutions are combined with blood products for perfusion. The solutions, systems and methods are also adaptable to drug delivery systems. In certain embodiments, the solutions are combined with additional additives at the point of use.
In one embodiment, a composition for use in a solution for perfusing an organ, such as a heart, is provided comprising one or more carbohydrates, one or more organ stimulants, and a plurality of amino acids that do not include asparagine, glutamine, or cysteine.
In another embodiment, a system for perfusing an organ, such as a heart, is provided comprising an organ and a substantially cell-free composition, where the compositions comprises one or more carbohydrates, one or more organ stimulants, and a plurality of amino acids that do not include asparagine, glutamine, or cysteine.
The foregoing and other objects and advantages of the invention will be appreciated more fully from the following further description thereof, with reference to the accompanying figures wherein:
The invention addresses deficiencies in the prior art by providing in various illustrated embodiments systems, methods, compositions, and solutions for maintaining an organ in a functioning state ex vivo under physiological or near physiological conditions. In one embodiment, the organ is a heart and is maintained in a beating state at a physiologic or near physiologic temperature during perfusion of a perfusion fluid, which may include one or more of the solutions described herein. According to certain embodiments, solutions with particular solutes and concentrations are selected and proportioned to enable the organ to function at physiologic or near physiologic conditions. For example, such conditions include maintaining organ function at or near a physiological temperature and/or preserving an organ in a state that permits normal cellular metabolism, such as protein synthesis.
In certain embodiments solutions are formed from compositions by combining components with a fluid, from more concentrated solutions by dilution, or from more dilute solutions by concentration. In exemplary embodiments, suitable solutions include one or more energy sources, one or more stimulants to assist the organ in continuing its normal physiologic function prior to and during transplantation, and one or more amino acids selected and proportioned so that the organ continues its cellular metabolism during perfusion. Cellular metabolism includes, for example conducting protein synthesis while functioning during perfusion. Some illustrative solutions are aqueous based, while other illustrative solutions are non-aqueous, for example organic solvent-based, ionic-liquid-based, or fatty-acid-based.
The solutions may include one or more energy-rich components to assist the organ in conducting its normal physiologic function. These components may include energy rich materials that are metabolizable, and/or components of such materials that an organ can use to synthesize energy sources during perfusion. Exemplary sources of energy-rich molecules include, for example, one or more carbohydrates. Examples of carbohydrates include monosaccharides, disaccharides, oligosaccharides, polysaccharides, or combinations thereof, or precursors or metabolites thereof. While not meant to be limiting, examples of monosaccharides suitable for the solutions include octoses; heptoses; hexoses, such as fructose, allose, altrose, glucose, mannose, gulose, idose, galactose, and talose; pentoses such as ribose, arabinose, xylose, and lyxose; tetroses such as erythrose and threose; and trioses such as glyceraldehyde. While not meant to be limiting, examples of disaccharides suitable for the solutions include (+)-maltose (4-O-(α-D-glucopyranosyl)-α-D-glucopyranose), (+)-cellobiose (4-O-(β-D-glucopyranosyl)-D-glucopyranose), (+)-lactose (4-O-(β-D-galactopyranosyl-β-D-glucopyranose), sucrose (2-O-(α-D-glucopyranosyl-β-D-fructofuranoside). While not meant to be limiting, examples of polysaccharides suitable for the solutions include cellulose, starch, amylose, amylopectin, sulfomucopolysaccharides (such as dermatane sulfate, chondroitin sulfate, sulodexide, mesoglycans, heparan sulfates, idosanes, heparins and heparinoids), and glycogen. In some embodiments, monossacharides, disaccharides, and polysaccharides of both aldoses, ketoses, or a combination thereof are used. One or more isomers, including enantiomers, diastereomers, and/or tautomers of monossacharides, disaccharides, and/or polysaccharides, including those described and not described herein, may be employed in the solutions described herein. In some embodiments, one or more monossacharides, disaccharides, and/or polysaccharides may have been chemically modified, for example, by derivatization and/or protection (with protecting groups) of one or more functional groups. In certain embodiments, carbohydrates, such as dextrose or other forms of glucose are preferred.
Other possible energy sources include adenosine triphosphate (ATP), co-enzyme A, pyruvate, flavin adenine dinucleotide (FAD), thiamine pyrophosphate chloride (co-carboxylase), β-nicotinamide adenine dinucleotide (NAD), β-nicotinamide adenine dinucleotide phosphate (NADPH), and phosphate derivatives of nucleosides, i.e. nucleotides, including mono-, di-, and tri-phosphates (e.g., UTP, GTP, GDF, and UDP), coenzymes, or other bio-molecules having similar cellular metabolic functions, and/or metabolites or precursors thereof. For example, phosphate derivatives of adenosine, guanosine, thymidine (5-Me-uridine), cytidine, and uridine, as well as other naturally and chemically modified nucleosides are contemplated.
In certain embodiments, one or more carbohydrates is provided along with a phosphate source, such as a nucleotide. The carbohydrate helps enable the organ to produce ATP or other energy sources during perfusion. The phosphate source may be provided directly through ATP, ADP, AMP, or other sources. In other illustrative embodiments, a phosphate is provided through a phosphate salt, such as glycerophosphate, sodium phosphate or other phosphate ions. A phosphate may include any form thereof in any ionic state, including protonated forms and forms with one or more counter ions.
The solutions may include one or more organ stimulants for assisting the organ's normal physiologic function during perfusion. In some illustrative embodiments, where the transplanted organ is a heart, cardio stimulants are provided to enable the heart to continue functioning (e.g., continue beating) during perfusion and transplantation. Such stimulants may include, for example, catecholamines, such as epinephrine and/or norepinephrine, which facilitate beating of the heart. Other cardio stimulants may be used, such as certain forms of peptides and/or polypeptides (e.g., vasopressin, Anthropleurin-A and Anthropleurin-B), and/or β1/β2-adrenoreceptor blocking agents (such as CGP 12177), buplinarol, pindolol, alprenolol, and cardiac glycosides. One or more natural products may also be used, such as digitalis (digoxin), palustrin, and/or ferulic acid. Stimulants such as those mentioned above can be included with the solutions or added at the point of use by the user.
In some instances, additional components are provided to assist the organ in conducting its metabolism during perfusion. These components include, for example, forms or derivatives of adenine and/or adenosine, which may be used for ATP synthesis, for maintaining endothelial function, and/or for attenuating ischemia and/or reperfusion injury. According to certain implementations, a magnesium ion source is provided with a phosphate, and in certain embodiments, with adenosine to further enhance ATP synthesis within the cells of the perfused organ.
As noted, the solution may include one or more amino acids, preferably a plurality of amino acids, to support protein synthesis by the organ's cells. Suitable amino acids include, for example, any of the naturally-occurring amino acids. The amino acids may be, in various enantiomeric or diastereomeric forms. For example, solutions may employ either D- or L-amino acids, or a combination thereof, i.e. solutions enantioenriched in more of the D- or L-isomer or racemic solutions. Suitable amino acids may also be non-naturally occurring or modified amino acids, such as citrulline, ornithine, homocystein, homoserine, β-amino acids such as β-alanine, amino-caproic acid, or combinations thereof.
Certain exemplary solutions include some but not all naturally-occurring amino acids. In some embodiments, solutions include essential amino acids. For example, a solution may be prepared with one or more or all of the following amino-acids:
In certain embodiments, non-essential and/or semi-essential amino acids are not included in the solutions. For example, in some embodiments, asparagine, glutamine, and/or cysteine are not included. In other embodiments, the solution contains one or more non-essential and/or semi-essential amino acids. Accordingly, in other embodiments, asparagine, glutamine, and/or cysteine are included.
The solutions may also contain electrolytes, particularly calcium ions for facilitating enzymatic reactions, cardiac contractility, and/or coagulation within the organ. Other electrolytes may be used, such as sodium, potassium, chloride, sulfate, magnesium and other inorganic and organic charged species or combinations thereof. It should be noted that any component provided hereunder may be provided, where valence and stability permit, in an ionic form, in a protonated or unprotonated form, in salt or free base form, or as ionic or covalent substituents in combination with other components that hydrolyze and make the component available in aqueous solutions, as suitable and appropriate.
In certain embodiments, the solutions contain buffering components. For example, suitable buffer systems include 2-morpholinoethanesulfonic acid monohydrate (MES), cacodylic acid, H2CO3/NaHCO3 (pKa1), citric acid (pKa3), bis(2-hydroxyethyl)-imino-tris-(hydroxymethyl)-methane (Bis-Tris), N-carbamoylmethylimidino acetic acid (ADA), 3-bis[tris(hydroxymethyl)methylamino]propane (Bis-Tris Propane) (pKa1), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), imidazole, N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N-morpholino)propanesulphonic acid (MOPS), NaH2PO4/Na2HPO4 (pKa2), N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), N-(2-hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid (HEPES), N-(2-hydroxyethyl)piperazine-N′-(2-hydroxypropanesulfonic acid) (HEPPSO), triethanolamine, N-[tris(hydroxymethyl)methyl]glycine (Tricine), tris hydroxymethylaminoethane (Tris), glycineamide, N,N-bis(2-hydroxyethyl)glycine (Bicine), glycylglycine (pKa2a2), N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), or a combination thereof. In some embodiments, the solutions contain sodium bicarbonate, potassium phosphate, or TRIS buffer.
The solutions may include other components to help maintain the organ and protect it against ischemia, reperfusion injury and other ill effects during perfusion. In certain exemplary embodiments these components may include hormones (e.g., insulin), vitamins (e.g., an adult multi-vitamin, such as multi-vitamin MVI-Adult™), and/or steroids (e.g., dexamethasone and SoluMedrol™).
In another aspect, a blood product is provided with the solution to support the organ during metabolism. Exemplary suitable blood products may include whole blood, and/or one or more components thereof such as blood serum, plasma, albumin, and red blood cells. In embodiments where whole blood is used, the blood may be passed through a leukocyte and platelet depleting filter to reduce pyrogens, antibodies and/or other items that may cause inflammation in the organ. Thus, in some embodiments, the solution employs whole blood that has been at least partially depleted of leukocytes and/or whole blood that has been at least partially depleted of platelets.
The solutions are preferably provided at a physiological temperature and maintained thereabout throughout perfusion and recirculation. As used herein, “physiological temperature” is referred to as temperatures between about 25° C. and about 37° C., for example, between about 30° C. and about 37° C., such as between about 34° C. and about 37° C.
Table 1 sets forth components that may be used in a preservative solution for preserving an organ as described herein.
The solutions described herein may be prepared from compositions having one or more components such as those described above in concentrations such as those described above. An exemplary embodiment of a composition adaptable for use in organ perfusion includes one or more components selected from Table 2. The amounts provided describe preferred amounts relative to other components in the table and may be scaled to provide compositions of sufficient quantity. In some embodiments, the amounts listed in Table 2 can vary by ±about 10% and still be used in the solutions described herein.
A solution may be prepared combining components selected by a user with an aqueous fluid to form a preservative solution. In an illustrative embodiment, one or more components from Table 2 are combined in the relative amounts listed therein per about 1000 mL of aqueous fluid to form a preservative solution for perfusing an organ, such as a heart. In some embodiments the quantity of aqueous fluid can vary ±about 10%.
In another aspect, solutions may be administered in combinations as desired by a medical operator.
In other illustrative embodiments, the solutions 15 and/or 17 may be provided systematically to optimize the effectiveness of the system. For example, as shown in
In some illustrative embodiments, the solutions described herein are combined with a blood product, such as whole blood or components thereof, which may also be oxygenated, to give a perfusion fluid. Additionally, synthetic blood products may be used as a substitute or in combination with blood products. Such combined solutions may be included in a perfusion circuit, such as those shown in
In other illustrative embodiments, one of the composition or solutions 13, 15, 17, or 19 may include one or more organ stimulants, such as cardio stimulants, and/or other components. The other components may include, for example, adenosine, a magnesium ion source, one or more phosphates, calcium ions, etc. In embodiments utilizing two or more solutions, such as those in
In one embodiment, a maintenance solution is made from the combination of a first solution, substantially formed from one or more amino acids, and a second solution, substantially formed from one or more carbohydrates, such as dextrose or glucose. The maintenance solution may also have additives, such as those described herein, administered at the point of use just prior to infusion into the organ perfusion system. For example, additional additives that can be included with the solution or added at the point of use by the user include hormones and steroids, such as dexamethasone and insulin, as well as vitamins, such as an adult multi-vitamin, for example adult multivitamins for infusion, such as MVI-Adult™. Additional small molecules and large bio-molecules may also be included with the solution or added at the point of use by the user, for example, therapeutics and/or components typically associated with blood or blood plasma, such as albumin.
In some embodiments, therapeutics that may be included in the compositions, solutions, and systems described herein include hormones, such as thyroid hormones, for example T3 and/or T4 thyroid hormones. Further therapeutics that may be included include drugs such as anti-arrhythmic drugs, for example, for heart therapy, and beta blockers. For instance, in certain embodiments, one or more thyroid hormones, one or more anti-arrhythmic drugs, and one or more beta blockers are added to the first solution, the second solution, and/or the maintenance solution either before or during perfusion of the organ. The above therapeutics may also be added directly to the system, for example to the perfusion circuit before or during perfusion of the organ.
Table 3 sets forth an exemplary first solution, comprising a tissue culture media having the components identified in Table 3 and combined with an aqueous fluid, which may be used as to perfuse an organ as described herein. The amounts of components listed in Table 3 are relative to each other and to the quantity of aqueous solution used. In some embodiments, about 500 mL of aqueous fluid is used. In other embodiments about 1 L of aqueous fluid is used. For example, combination of about 500 mL of first solution with 500 mL of second solution affords a maintenance solution of about 1 L. In some embodiments, the quantity of aqueous solution can vary ±about 10%. The component amounts and the quantity of aqueous solution may be scaled as appropriate for use. The pH of the first solution, in this embodiment, may be adjusted to be about 7.0 to about 8.0, for example about 7.3 to about 7.6.
Since amino acids are the building blocks of proteins, the unique characteristics of each amino acid impart certain important properties on a protein such as the ability to provide structure and to catalyze biochemical reactions. The selection and concentrations of the amino acids provided in the first solution provide support of normal physiologic functions such as metabolism of sugars to provide energy, regulation of protein metabolism, transport of minerals, synthesis of nucleic acids (DNA and RNA), regulation of blood sugar and support of electrical activity, in addition to providing protein structure. Additionally, the concentrations of specific amino acids found in the first solution can be used to predictably stabilize the pH of the first solution and/or other solutions and fluids to which the first solution may be added, for example the maintenance solution and/or the perfusion fluid.
Table 4 provides an exemplary second solution 15, comprising a solution which may be used with the systems of
Additional components may be included in the first or second solution, the maintenance solution, and/or the priming solution and may include one or more of those set forth in Table 5. These additional or supplemental components may be added individually, in various combinations, or all at once as a composition. For example, in certain embodiments, the epinephrine, insulin, and MVI-Adult™, listed in Table 5, are added to the maintenance solution. In another example, the SoluMedrol™ and the sodium bicarbonate, listed in Table 5, are added to the priming solution. The additional components may also be combined in one or more combinations or all together and placed in solution before being added to the first or second solution or to the maintenance solution. These additional components may be degraded or otherwise inactivated if subjected to sterilization, and, as such, may be appropriately applied directly to the perfusion circuit or to a first 13 or second 15 solution after sterilization, such as described with regard to the composition or solution 19 of
As described above, in certain illustrative embodiments, solutions are used to perfuse an organ prior to transplantation. In certain embodiments one or more solutions are applied to maintain the organ, and a separate solution is applied to prime the organ prior to applying one or more maintenance solutions. Certain exemplary components for priming solutions are identified in Table 6. In some embodiments, the priming solutions includes one or more carbohydrates. The component amounts in Table 6 are relative to each other and to the amount of aqueous solvent (about 500 mL) and may be scaled as appropriate. In certain embodiments, the quantity of aqueous solvent varies ±about 10%.
In some illustrative embodiments, the invention combines solutions as described herein in desired sequences to provide for improved physiological performance of the organ. Although the first and second solutions are shown above, and referenced as solutions 13 and 15 in
In some illustrative embodiments, the solutions contemplated herein may be adapted for use with an organ perfusion system such as that described in U.S. Pat. Nos. 6,100,082 or 6,046,046, or PCT application PCT/US98/19912, the specifications of which are hereby incorporated by reference in their entirety.
Certain embodiments of the first solution include epinephrine and a plurality of amino acids. In certain embodiments, the first solution includes electrolytes, such as calcium and magnesium. The first solution may also include other components such as adenosine and/or one or more components from Table 3. In certain embodiments a second solution includes one or more carbohydrates and may also include a phosphate source. The second solution is typically maintained at a pH of about 5.0 to about 6.5, for example of about 5.5 to about 6.0.
In certain embodiments methods for perfusing an organ are provided through the use of solutions described herein, such as through the systems illustrated in
In one illustrative embodiment, the system described in
In one embodiment, a composition for use in a solution for perfusing an organ, such as a heart, is provided comprising one or more carbohydrates, one or more organ stimulants, and a plurality of amino acids that do not include asparagine, glutamine, or cysteine. The composition may also include other substances, such as those used in solutions described herein.
In another embodiment, a system for perfusing an organ, such as a heart, is provided comprising an organ and a substantially cell-free composition, comprising one or more carbohydrates, one or more organ stimulants, and a plurality of amino acids that do not include asparagine, glutamine, or cysteine. Substantially cell-free includes systems that are substantially free from cellular matter; in particular, systems that are not derived from cells. For example, substantially cell-free includes compositions and solutions prepared from non-cellular sources.
In another aspect, the solutions and systems may be provided in the form of a kit that includes one or more organ maintenance solutions. An exemplary maintenance solution may include components identified above in one or more fluid solutions for organ perfusion. In certain embodiments, the maintenance solution may include multiple solutions, such as a first solution and a second solution and/or a supplemental composition or solution, or may include dry components that may be regenerated in a fluid to form one or more solutions for organ perfusion. The kit may also comprise one or more concentrated solutions which, on dilution, provide a first, second, and/or supplemental solution as described herein. The kit may also include a priming solution. In an exemplary embodiment, the maintenance solution includes a first solution and second solution such as those described above, and a priming solution such as that described above.
In certain embodiments, the kit is provided in a single package, wherein the kit includes one or more solutions (or components necessary to formulate the one or more solutions by mixing with an appropriate fluid), and instructions for sterilization, flow and temperature control during perfusion and use and other information necessary or appropriate to apply the kit to organ perfusion. In certain embodiments, a kit is provided with only a single solution (or set of dry components for use in a solution upon mixing with an appropriate fluid), and the single solution (or set of dry components) is provided along with a set of instructions and other information or materials necessary or useful to operate the solution in a perfusion apparatus or system.
In another aspect, the systems, solutions and methods may be used to deliver therapeutics to an organ during perfusion. For example, one or more of the solutions and/or systems described above may include one or more drugs, biologics, gene therapy vectors, or other therapeutics which are delivered to the organ during perfusion. Suitable exemplary therapeutics may include drugs, biologics, or both. Suitable drugs may include, for example, anti fungals, anti-microbials or anti-biotics, anti-inflammatories, anti-proliferatives, anti-virals, steroids, retinoids, NSAIDs, vitamin D3 and vitamin D3 analogs, calcium channel blockers, complement neutralizers, ACE inhibitors, immuno-suppressants, and other drugs. Suitable biologics may include proteins; suitable biologics may also include vectors loaded with one or more genes for gene therapy application.
For example, suitable steroids include but are not limited to androgenic and estrogenic steroid hormones, androgen receptor antagonists and 5-α-reductase inhibitors, and corticosteroids. Specific examples include but are not limited to alclometasone, clobetasol, fluocinolone, fluocortolone, diflucortolone, fluticasone, halcinonide, mometasone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, and dexamethasone, and various esters and acetonides thereof.
Suitable retinoids include but are not limited to retinol, retinal, isotretinoin, acitretin, adapalene, tazarotene, and bexarotene.
Suitable NSAIDs include but are not limited to naproxen, suprofen, ketoprofen, ibuprofen, flurbiprofen, diclofenac, indomethacin, celecoxib, and rofecoxib.
Suitable vitamin D3 analogues include but are not limited to doxercalciferol, seocalcitol, calcipotriene, tacalcitol, calcitriol, ergocalciferol, and calcifediol.
Suitable anti-viral agents include but are not limited to trifluridine, cidofovir, acyclovir, penciclovir, famciclovir, valcyclovir, gancyclovir, and docosanol.
Suitable human carbonic anhydrase inhibitors include but are not limited to methazoliamide, acetazolamide, and dorzolamide.
Suitable anti-proliferative agents include but are not limited to 5-FU, taxol, daunorubicin, and mitomycin.
Suitable antibiotic (antimicrobial) agents include but are not limited to bacitracin, chlorhexidine, chlorhexidine digluconate, ciprofloxacin, clindamycin, erythromycin, gentamicin, lomefloxacin, metronidazole, minocycline, moxifloxacin, mupirocin, neomycin, ofloxacin, polymyxin B, rifampicin, ruflozacin, tetracycline, tobramycin, triclosan, and vancomycin. The antiviral and antibacterial prodrugs described herein may be used to treat appropriately responsive systemic infections.
Certain experimental data are available to describe certain embodiments of the solutions described herein and their use in organ perfusion. Certain data are set for in
This application incorporates by reference the specification from each of the following applications: U.S. application Ser. No. 09/534,092, filed on Mar. 23, 2000, PCT/US98/19912, filed on Sep. 23, 1998, U.S. application Ser. No. 09/054,698 filed on Apr. 3, 1998, and U.S. application Ser. No. 08/936,062 filed on Sep. 23, 1997.
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the forgoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. For example, a variety of systems and/or methods may be implemented based on the disclosure and still fall within the scope of the invention. Other aspects, advantages, and modifications are within the scope of the following claims.
This application claims the benefit of U.S. patent application Ser. No. 11/246,919, filed on Oct. 7, 2005; U.S. Provisional Patent Application Ser. No. 60/694,971, filed on Jun. 28, 2005; and U.S. Provisional Patent Application Ser. No. 60/725,168, filed on Oct. 6, 2005, and entitled Systems and Methods for Ex-Vivo Organ Care. The specifications of each of the foregoing are incorporated by reference herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3253595 | Keller, Jr. et al. | May 1966 | A |
3388803 | Scott | Jun 1968 | A |
3406531 | Koski et al. | Oct 1968 | A |
3468136 | Koski et al. | Sep 1969 | A |
3537956 | Falcone | Nov 1970 | A |
3545221 | Koski et al. | Dec 1970 | A |
3545605 | Robins | Dec 1970 | A |
3587567 | Schiff | Jun 1971 | A |
3607646 | de Roissart | Sep 1971 | A |
3632473 | Belzer et al. | Jan 1972 | A |
3639084 | Goldhaber | Feb 1972 | A |
3654085 | Fritz et al. | Apr 1972 | A |
3660241 | Michielsen | May 1972 | A |
3738914 | Thorne et al. | Jun 1973 | A |
3772153 | De Roissart | Nov 1973 | A |
3777507 | Burton et al. | Dec 1973 | A |
3843455 | Bier et al. | Oct 1974 | A |
3851646 | Sarns | Dec 1974 | A |
3881990 | Burton et al. | May 1975 | A |
3995444 | Clark et al. | Dec 1976 | A |
4186565 | Toledo-Pereyra | Feb 1980 | A |
4231354 | Kurtz et al. | Nov 1980 | A |
4415556 | Bretschneider | Nov 1983 | A |
4598697 | Numazawa et al. | Jul 1986 | A |
4605644 | Foker | Aug 1986 | A |
4666425 | Fleming | May 1987 | A |
4719201 | Foker | Jan 1988 | A |
4723939 | Anaise | Feb 1988 | A |
4745759 | Bauer et al. | May 1988 | A |
4759371 | Franetzki | Jul 1988 | A |
4801299 | Brendel | Jan 1989 | A |
4847470 | Bakke | Jul 1989 | A |
4920044 | Bretan, Jr. | Apr 1990 | A |
5051352 | Martindale et al. | Sep 1991 | A |
5066578 | Wikman-Coffelt | Nov 1991 | A |
5141847 | Sugimachi et al. | Aug 1992 | A |
5145771 | Lemasters et al. | Sep 1992 | A |
5157930 | McGhee et al. | Oct 1992 | A |
5200398 | Strasberg et al. | Apr 1993 | A |
5217860 | Fahy et al. | Jun 1993 | A |
5285657 | Bacchi et al. | Feb 1994 | A |
5306711 | Andrews | Apr 1994 | A |
5326706 | Yland et al. | Jul 1994 | A |
5338662 | Sadri | Aug 1994 | A |
5356593 | Heiberger et al. | Oct 1994 | A |
5356771 | O'Dell | Oct 1994 | A |
5358931 | Rubinsky et al. | Oct 1994 | A |
5362622 | O'Dell et al. | Nov 1994 | A |
5370989 | Stern et al. | Dec 1994 | A |
5381510 | Ford et al. | Jan 1995 | A |
5385821 | O'Dell et al. | Jan 1995 | A |
5395314 | Klatz et al. | Mar 1995 | A |
5405742 | Taylor | Apr 1995 | A |
5407669 | Lindstrom et al. | Apr 1995 | A |
5407793 | Del Nido et al. | Apr 1995 | A |
5472876 | Fahy | Dec 1995 | A |
5473791 | Holcomb et al. | Dec 1995 | A |
5494822 | Sadri | Feb 1996 | A |
5498427 | Menasche | Mar 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5514536 | Taylor | May 1996 | A |
5552267 | Stern et al. | Sep 1996 | A |
5554123 | Herskowitz | Sep 1996 | A |
5554497 | Raymond | Sep 1996 | A |
5571801 | Segall et al. | Nov 1996 | A |
5584804 | Klatz et al. | Dec 1996 | A |
5586438 | Fahy | Dec 1996 | A |
5588816 | Abbott et al. | Dec 1996 | A |
5599173 | Chen et al. | Feb 1997 | A |
5599659 | Brasile et al. | Feb 1997 | A |
5613944 | Segall et al. | Mar 1997 | A |
5643712 | Brasile | Jul 1997 | A |
5654266 | Chen et al. | Aug 1997 | A |
5656420 | Chien | Aug 1997 | A |
5679565 | Mullen et al. | Oct 1997 | A |
5693462 | Raymond | Dec 1997 | A |
5698536 | Segall et al. | Dec 1997 | A |
5699793 | Brasile | Dec 1997 | A |
5702881 | Brasile et al. | Dec 1997 | A |
5716378 | Minten | Feb 1998 | A |
5723281 | Segall et al. | Mar 1998 | A |
5733894 | Segall et al. | Mar 1998 | A |
5747071 | Segall et al. | May 1998 | A |
5752929 | Klatz et al. | May 1998 | A |
5770149 | Raible | Jun 1998 | A |
5776063 | Dittrich et al. | Jul 1998 | A |
5786136 | Mayer | Jul 1998 | A |
5787544 | Meade | Aug 1998 | A |
5807737 | Schill et al. | Sep 1998 | A |
5823799 | Tor et al. | Oct 1998 | A |
5843024 | Brasile | Dec 1998 | A |
5856081 | Fahy | Jan 1999 | A |
5882328 | Levy et al. | Mar 1999 | A |
5965433 | Gardetto et al. | Oct 1999 | A |
5998240 | Hamilton et al. | Dec 1999 | A |
6024698 | Brasile | Feb 2000 | A |
6034109 | Ramasamy et al. | Mar 2000 | A |
6042550 | Haryadi et al. | Mar 2000 | A |
6046046 | Hassanein | Apr 2000 | A |
6050987 | Rosenbaum | Apr 2000 | A |
6100082 | Hassanein | Aug 2000 | A |
6110139 | Loubser | Aug 2000 | A |
6110504 | Segall et al. | Aug 2000 | A |
6144444 | Haworth et al. | Nov 2000 | A |
6168877 | Pedicini et al. | Jan 2001 | B1 |
6365338 | Bull et al. | Apr 2002 | B1 |
6375611 | Voss et al. | Apr 2002 | B1 |
6375613 | Brasile | Apr 2002 | B1 |
6389308 | Shusterman | May 2002 | B1 |
6402461 | Tebby | Jun 2002 | B1 |
6475716 | Seki | Nov 2002 | B1 |
6490880 | Walsh | Dec 2002 | B1 |
6492103 | Taylor | Dec 2002 | B1 |
6492745 | Colley, III et al. | Dec 2002 | B1 |
6524785 | Cozzone et al. | Feb 2003 | B1 |
6569615 | Thatte et al. | May 2003 | B1 |
6582953 | Brasile | Jun 2003 | B2 |
6600941 | Khuri | Jul 2003 | B1 |
6609987 | Beardmore | Aug 2003 | B1 |
6631830 | Ma et al. | Oct 2003 | B2 |
6642045 | Brasile | Nov 2003 | B1 |
6673594 | Owen et al. | Jan 2004 | B1 |
6696238 | Murphy et al. | Feb 2004 | B2 |
6740484 | Khirabadi et al. | May 2004 | B1 |
6783328 | Lucke et al. | Aug 2004 | B2 |
6792309 | Noren | Sep 2004 | B1 |
6794124 | Steen | Sep 2004 | B2 |
6811965 | Vodovotz et al. | Nov 2004 | B2 |
6878339 | Akiyama et al. | Apr 2005 | B2 |
6925324 | Shusterman | Aug 2005 | B2 |
6953655 | Hassanein et al. | Oct 2005 | B1 |
6974436 | Aboul-Hosn et al. | Dec 2005 | B1 |
7001354 | Suzuki et al. | Feb 2006 | B2 |
7008380 | Rees et al. | Mar 2006 | B1 |
7238165 | Vincent et al. | Jul 2007 | B2 |
7316666 | Entenman et al. | Jan 2008 | B1 |
7452711 | Daykin | Nov 2008 | B2 |
7572622 | Hassanein et al. | Aug 2009 | B2 |
7651835 | Hassanein et al. | Jan 2010 | B2 |
8304181 | Hassanein et al. | Nov 2012 | B2 |
8409846 | Hassanein et al. | Apr 2013 | B2 |
8420380 | Fishman et al. | Apr 2013 | B2 |
8465970 | Hassanein et al. | Jun 2013 | B2 |
8535934 | Hassanein et al. | Sep 2013 | B2 |
8585380 | Hassanein et al. | Nov 2013 | B2 |
8822203 | Hassanein et al. | Sep 2014 | B2 |
9215867 | Hassanein et al. | Dec 2015 | B2 |
9457179 | Hassanein et al. | Oct 2016 | B2 |
9462802 | Fishman et al. | Oct 2016 | B2 |
20010003652 | Freeman | Jun 2001 | A1 |
20010025191 | Montgomery | Sep 2001 | A1 |
20020012988 | Brasile | Jan 2002 | A1 |
20020013220 | Wang et al. | Jan 2002 | A1 |
20020102720 | Steen | Aug 2002 | A1 |
20020132220 | Berens et al. | Sep 2002 | A1 |
20020151950 | Okuzumi | Oct 2002 | A1 |
20020164795 | Gen | Nov 2002 | A1 |
20020177117 | Wolf | Nov 2002 | A1 |
20020187132 | McGregor et al. | Dec 2002 | A1 |
20030011604 | Capers | Jan 2003 | A1 |
20030040665 | Khuri et al. | Feb 2003 | A1 |
20030050689 | Matson | Mar 2003 | A1 |
20030053998 | Daemen et al. | Mar 2003 | A1 |
20030073227 | Hull et al. | Apr 2003 | A1 |
20030074760 | Keller | Apr 2003 | A1 |
20030086830 | Haywood et al. | May 2003 | A1 |
20030135152 | Kollar et al. | Jul 2003 | A1 |
20030147466 | Liang | Aug 2003 | A1 |
20040015042 | Vincent et al. | Jan 2004 | A1 |
20040017658 | Lo et al. | Jan 2004 | A1 |
20040018966 | Segall et al. | Jan 2004 | A1 |
20040029096 | Steen | Feb 2004 | A1 |
20040038192 | Brasile | Feb 2004 | A1 |
20040058432 | Owen et al. | Mar 2004 | A1 |
20040082057 | Alford et al. | Apr 2004 | A1 |
20040086578 | Segall et al. | May 2004 | A1 |
20040102415 | Thatte et al. | May 2004 | A1 |
20040102678 | Haindl | May 2004 | A1 |
20040106958 | Mathis et al. | Jun 2004 | A1 |
20040110800 | Bril et al. | Jun 2004 | A1 |
20040115689 | Augello et al. | Jun 2004 | A1 |
20040138542 | Khuri et al. | Jul 2004 | A1 |
20040168341 | Petersen et al. | Sep 2004 | A1 |
20040170950 | Prien | Sep 2004 | A1 |
20040171138 | Hassanein et al. | Sep 2004 | A1 |
20040193096 | Cooper | Sep 2004 | A1 |
20040202993 | Poo et al. | Oct 2004 | A1 |
20040221719 | Wright et al. | Nov 2004 | A1 |
20040224298 | Brassil et al. | Nov 2004 | A1 |
20040235142 | Schein et al. | Nov 2004 | A1 |
20040236170 | Kim | Nov 2004 | A1 |
20040248281 | Wright et al. | Dec 2004 | A1 |
20050010118 | Toyoda et al. | Jan 2005 | A1 |
20050019917 | Toledo-Pereyra et al. | Jan 2005 | A1 |
20050142532 | Poo et al. | Jun 2005 | A1 |
20050147958 | Hassanein et al. | Jul 2005 | A1 |
20050153271 | Wenrich | Jul 2005 | A1 |
20050170019 | Roth | Aug 2005 | A1 |
20050182349 | Linde et al. | Aug 2005 | A1 |
20050187469 | Phillips | Aug 2005 | A1 |
20050253390 | Blazek | Nov 2005 | A1 |
20060039870 | Turner | Feb 2006 | A1 |
20060074470 | Bartels et al. | Apr 2006 | A1 |
20060121438 | Toledo-Pereyra et al. | Jun 2006 | A1 |
20060124130 | Bonassa | Jun 2006 | A1 |
20060134073 | Naka et al. | Jun 2006 | A1 |
20060148062 | Hassanein et al. | Jul 2006 | A1 |
20060154357 | Hassanein et al. | Jul 2006 | A1 |
20060154359 | Hassanein et al. | Jul 2006 | A1 |
20060160204 | Hassanein et al. | Jul 2006 | A1 |
20060292544 | Hassanein et al. | Dec 2006 | A1 |
20070196461 | Weers | Aug 2007 | A1 |
20070275364 | Hassanein et al. | Nov 2007 | A1 |
20080017191 | Davies et al. | Jan 2008 | A1 |
20080017194 | Hassanein et al. | Jan 2008 | A1 |
20080234768 | Hassanein et al. | Sep 2008 | A1 |
20080286746 | Poo et al. | Nov 2008 | A1 |
20090142830 | Yamashiro et al. | Jun 2009 | A1 |
20090143417 | Smith et al. | Jun 2009 | A1 |
20090197240 | Fishman et al. | Aug 2009 | A1 |
20090197241 | Fishman et al. | Aug 2009 | A1 |
20090197292 | Fishman et al. | Aug 2009 | A1 |
20090197324 | Fishman et al. | Aug 2009 | A1 |
20090197325 | Fishman et al. | Aug 2009 | A1 |
20090215022 | Page et al. | Aug 2009 | A1 |
20090312724 | Pipkin et al. | Dec 2009 | A1 |
20100056966 | Toth | Mar 2010 | A1 |
20100092939 | Belous et al. | Apr 2010 | A1 |
20110076666 | Brassil | Mar 2011 | A1 |
20110136096 | Hassanein et al. | Jun 2011 | A1 |
20110190572 | Brophy et al. | Aug 2011 | A1 |
20110212431 | Bunegin et al. | Sep 2011 | A1 |
20120277681 | Kravitz et al. | Nov 2012 | A1 |
20130011823 | Hassanein et al. | Jan 2013 | A1 |
20130078710 | Hassanein et al. | Mar 2013 | A1 |
20130157248 | Fishman et al. | Jun 2013 | A1 |
20130295552 | Hassanein et al. | Nov 2013 | A1 |
20140017658 | Steinman et al. | Jan 2014 | A1 |
20140017660 | Steinman et al. | Jan 2014 | A1 |
20140135738 | Panian | May 2014 | A1 |
20150079580 | Hassanein et al. | Mar 2015 | A1 |
20150230453 | Fontes et al. | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
2881613 | Nov 2007 | CA |
1232723 | Oct 1999 | CN |
1269471 | Oct 2000 | CN |
4201259 | Jul 1993 | DE |
10121159 | Nov 2002 | DE |
0347923 | Dec 1989 | EP |
0347923 | Dec 1989 | EP |
0376763 | Jul 1990 | EP |
0376763 | Jul 1990 | EP |
1942726 | Jul 2008 | EP |
H02-282301 | Nov 1990 | JP |
02-306901 | Dec 1990 | JP |
H03-74302 | Mar 1991 | JP |
04-099701 | Mar 1992 | JP |
H04-128201 | Apr 1992 | JP |
06-056601 | Mar 1994 | JP |
06-305901 | Nov 1994 | JP |
08-511012 | Nov 1996 | JP |
2001061956 | Mar 2001 | JP |
2001516768 | Oct 2001 | JP |
2004513889 | May 2004 | JP |
2004525290 | Aug 2004 | JP |
2004529938 | Sep 2004 | JP |
2004529938 | Sep 2004 | JP |
2008-515914 | May 2008 | JP |
2009-521931 | Jun 2009 | JP |
2011-511000 | Apr 2011 | JP |
6144238 | Jun 2017 | JP |
WO-8805261 | Jul 1988 | WO |
WO-9502326 | Jan 1995 | WO |
WO-9531897 | Nov 1995 | WO |
WO-9618293 | Jun 1996 | WO |
WO-9629865 | Oct 1996 | WO |
WO-9746091 | Dec 1997 | WO |
WO-9915011 | Apr 1999 | WO |
WO-0022927 | Apr 2000 | WO |
WO-0060936 | Oct 2000 | WO |
WO-0226034 | Apr 2002 | WO |
WO-0235929 | May 2002 | WO |
WO-02089571 | Nov 2002 | WO |
WO-2004026031 | Apr 2004 | WO |
WO-2006042138 | Apr 2006 | WO |
WO-2006076590 | Jul 2006 | WO |
WO-2006124820 | Nov 2006 | WO |
WO-2007079185 | Jul 2007 | WO |
WO-2007124044 | Nov 2007 | WO |
WO-2008106724 | Sep 2008 | WO |
WO-2009099939 | Aug 2009 | WO |
WO-2009099939 | Aug 2009 | WO |
WO-2011072012 | Jun 2011 | WO |
WO-2013068752 | May 2013 | WO |
WO-2014059316 | Apr 2014 | WO |
WO-2015154170 | Oct 2015 | WO |
Entry |
---|
Botha, P., “Extended Donor Criteria in Lung Transplantation”, Current Opinion in Organ Transplantation, 14:206-210, 2009 (5 pages). |
Johnston, R., “What's Normal About DLCO?”, PFT Blog, Jan. 1, 2014 (17 pages). |
Chien, et al., “Functional Studies of the Heart During a 24-Hour Preservation Using a New Autoperfusion Preparation,” The Journal of Heart and Lung Transplantation, 10(3):401-8 (1991) (8 pages). |
Howarth, F.C. et al., “Effects of extracellular magnesium and beta adrenergic stimulation on contractile force and magnesium mobilization in the Isolated rat heart”, Magnesium Research, 7:187-197, 1994 (13 pages). |
Moisiuk, Y. et al., “Histidine-Tryptophan-Ketoglutarate Versus Euro-Collins for Preservation of Kidneys From Non-Heart-Beating Donors,” Transplantation Proceedings, 28(1):202 (1996) (1 page). |
Poston, R.S. et al., “Optimizing Donor Heart Outcome After Prolonged Storage With Endothelial Function Analysis and Continuous Perfusion”, Ann Thorac Surg, 78:1362-1370, 2004 (9 pages). |
Shimokawa, S. et al., “A New Lung Preservation Method of Topical Cooling by Ambient Cold Air: An Experimental Study,” Transplantation Proceedings, 23 (1):653-54 (1991) (2 pages). |
“Glucose”, The Merck Index, Entry 4535, 19th Edition, Merck & Co., INc., Rahway, NJ, pp. 699-700, 1989. |
Ahmad, et al., “A Pathophysiologic Study of the Kidney Tubule to Optimize Organ Preservation Solutions”, Kidney Int. 66(1):77-90 (2004). |
Aitchison, et al., “Nitric Oxide During Perfusion Improves Posttransplantation Function of Non-Heart-Beating Donor Lungs”, Transplantation, 75(12):1960-1964, Jun. 27, 2003, 5 pages. |
Anathaswamy, Anal: “Machine keeps organs alive for longer.” New Scientist.com from New Scientist Print Edition. (Aug. 16, 2001, 15:16). (http://www.newscientist.com/article.ns?id=dn1168&print=true). |
Aoki, et al., “Anti-CD18 Attenuates Deleterious Effects of Cardiopulmonary Bypass and Hypothermic Circulatory Arrest in Piglets”, J. Card. Surg., 10:407-417, 1995. |
Associated Press: “Heart kept beating outside the body.” CNN News Health Section (Oct. 7, 2001, 02:59) (CNN.com/Health with WebMD.com). |
Bando, et al., “Oxygenated Perfluorocarbon, Recombinant Human Superoxide Dismutase, and Catalase Ameliorate Free Radical Induced Mycardial Injury During Heart Preservation and Transplantation”, J. Tohorac Cardiovasc Surg, 96:930-938, Dec. 1988. |
Barinov, et al. “Hormonal-metabolic disturbances during biological preservation of the heart,” Fiziol. ZH., (Kiev), 29(3):293-299 (1983) (7 pages)—Russian Language. |
Barr Laboratories, “History of Transplantation and Organ Preservation”, Barr Laboratories, Inc. 2004, 4 pages. |
Benichou, et al., “Canine and Human Liver Preservation for 6 to 18 Hr by Cold Infusion”, Transplantation, 24(6):407-411, Dec. 1977. |
Birkett, Donald J. et al: “The fatty acid content and drug binding characteristics of commercial albumin preparations.” Clinica Chimerica Acts, vol. 85, pp. 253-258(1978). |
Blanchard, et al., “Techniques for Perfusion and Storage of Heterotopic Heart Transplants in Mice”, Microsurgery, 6:169-174, 1985. |
Boggi, et al,. “Pancreas preservation with University of Wisconsin and Celsior Solutions”, Transplant Proc., 36(3):563-565, 2004. |
Boggi, et al., “Pancreas Preservation with University of Wisconsin and Celsior Solutions: A Single-Center, Prospective, Randomized Pilot Study”, Transplantation, 77(8):186-190, 2004. |
Boyle, Jr., et al., “Ischemia-Reperfusion Injury”, Ann. Thorac. Surg., 64:524-530, 1997. |
Brandes, H. et al. “Influence of high molecular dextrans on lung function in an ex vivo porcine lung model,” J. of Surgical Research, 101:2, 225-231 (2001). |
Brasile, et al., “Organ Preservation without Extreme Hypothermia Using an Oxygen Supplemented Perfusate”, Art. Cells. Blood Subs. and Immob. Biotech, 22(4):1463-1468, 1994. |
Burt, et al., “Myocardial Function after Preservation for 24 Hours”, Jour Thorac and Cardiovascular Surgery, 92(2):238-246, 1986. |
Calhoon, et al., “Twelve-Hour Canine Heart Preservation with a Simple, Portable Hypothermic Organ Perfusion Device”, Ann. Thorac. Surg., 62:91-93, 1996. |
Canelo, et al., “Experience with Hystidine Tryptophan Ketoglutarate Versus University Wisconsin Preservation Solutions in Transplantation”, Int. Surg., 88(3):145-151, 2003. |
Carrera, Stephen J.: “Machine may be organ transplant breakthrough.” USA Today.com Health and Science (Aug. 8, 2001) (http://www.usatoday.com/news/health/2001-08-25-organ.htm). |
Chambers, et al., “Lont-Term Preservation of the Heart: The Effect of Infusion Pressure During Continuous Hypothemic Cardioplegia”, Jour of Heart and Lung Transp., 11(4):665-675, 1992. |
Chen, et al,. “Development of New Organ Preservation Solutions in Kyoto University”, Yonsei Medical Journal, 46(6):1107-1140, 2004. |
Chien, et al., “A Simple Technique for Multiorgan Preservation”, Journal of Thor. and Card. Surg., 95(1):55-61, 1988. |
Chien, et al., “Canine Lung Transplantation after More than Twenty-Four Hours of Normothermic Preservation”, J. Heart Lung Transplant., 16:3340-3351, 1997. |
Christophl, et al., “A Comparison of Standard and Rapid Infusion Methods of Liver Preservation During Multi-Organ Procurement”, Aust. N.Z. J. Surg, 61(9):692-694, 1991. |
Cimino, Adria: “Doctor develops device to preserve donated organs.” Mass High Tech, the Journal of New England Technology Online (Sep. 17, 2001) (No url), 2 pages. |
Collins, “Organ Transplantation: What is the State of the Art?”, Ann. Surg., 238(6 Suppl.):S72-S89, 2003. |
Cronin, David et al: “Liver Transportation at the University of Chicago.” Clinical Transplants, Ch. 21, pp. 231-237 (1991). |
Daemen, et al., “Short-Term Outcome of Kidney Transplants from Non-Heart-Beating Donors after Preservation by Machine Perfusion”, Transpl Int., 9(Suppl. 1):S76-S80, 1996. |
Demertzis, et al., “University of Wisconsin Versus St. Thomas' Hospital Solution for Human Donor Heart Preservation”, Ann. Thorac. Surg., 55:1131-1137, 1993. |
Den Butter, et al., “Comparison of Solutions for Preservation of the Rabbit Liver as Tested by Isolation Perfusion”, Transpl. Int., 8(6):466-471, 1995. |
Denham, et al., “Twenty-Four Hour Canine Renal Preservation by Pulsatile Perfusion”, Hypothermic Storage, and Combinations of the Two Methods, Transplant Proc., 9(3):1553-1556, 1977. |
Dobrian, et al., “In Vitro Formation of Exidatively-Modified and Reassembled Human Low-Density Lipoproteins”, Biochimica et Biophysica Acta (BBA), 1169:12-24, 1993. |
Dow Jones and Company: “The Nation: warm-storage devices may aid organ transplants.” Dow Jones Publication Library, Aug. 26, 2001, 1 page. |
Drexler, et al., “Effect of L-Arginine on Coronary Endothelial Function in Cardiac Transplant Recipients”, Circulation, 89(4):1615-1623, 1994. |
Eiseman, et al., “A Disposable Liver Perfusion Chamber”, Surgery, 6:1163-1166, 1966. |
Engelman, et al., “Influence of Steroids on Complement and Cytokine Generation After Cardiopulmonary Bypass”, Ann. Thorac. Surg., 60(3):801-804, 1995. |
European Search Report for European Patent Application No. 08795820.3 dated Apr. 17, 2014. 6 pages. |
European Search Report for European Patent Application No. 09707471.0 dated May 27, 2014. 7 pages. |
European Search Report issued in EP12770852.7, dated Sep. 23, 2014, 8 pages. |
Fabregas, Lisa: “UPMC tests machine to aid heart transplants.” Pittsburgh Tribune Review Live.com (Feb. 24, 2002) (http://www.pittsburghlive.com/x/pittsburghtrib/print_19181.html). |
Faggian, et al., “Donor Organ preservation in High-Risk Cardiac Transplantation”, Transplant Proc., 36:617-619, 2004. |
Featherstone et al. “Comparison of Phosphodiesterase Inhibitors of Differing Isoenzyme Selectivity Addes to St. Thomas Hospital Cardioplegic Solution Used for Hypothermic Preservation of Rat Lungs.” Am. J. Respir. Crit. Care Med. Mar. 2000. 162(3):850-856. |
Fehrenberg, et al., “Protective Effects of B2 Preservation Solution in Comparison to a Standard Solution (Histidine-Tryptophan-Ketoglutarate/Bretschneider) in a Model of Isolated Autologous Hemopherfused Porcine Kidney”, Nephron Physiol, 96:52-58, 2004. |
Ferrera, et al., “Comparison of Different Techniques of Hypothermic Pig Heart Preservation”, Ann. Thorac. Surg., 57(5):1233-1239, 1994. |
File History for U.S. Appl. No. 60/616,835, filed Oct. 7, 2004. 82 pages. |
File History for U.S. Appl. No. 60/694,971, filed Jun. 28, 2005. 280 pages. |
File History for U.S. Appl. No. 60/725,168, filed Oct. 6, 2005. 699 pages. |
Finn, et al., “Effects of Inhibition of Complement Activation Using Recombinant Soluble Complement Receptor 1 on Neutrophil CD11B/CD18 and L-Selectin Expression and Release of Interleukin-8 and Elastase in Simulated Cardiopulmonary Bypass”, J. Thorac. Cardiovasc. Surg., 111(2):451-459, 1996. |
Forcade, et al., “A New Method of Kidney Preservation with Collins' Solution”, Biomed., 21(7):308-311, 1974. |
Fraser, et al., “Evaluation of Current Organ Preservation Method for Heart-Lung Transplantation”, Transplant. Proc., 201(1 Suppl):987-990, 1988. |
Grynberg et al. “Fatty acid oxidation in the heart,” Journal of Cardiovascular Pharmacology, 28(Suppl. 1):S11-S17 (1996) (8 pages). |
Guarrera, et al., “Pulsatile Machine Perfusion with Vasosol Solution Improves Early Graft Function after Cadaveric Renal Transplantation”, Transplantation, 77(8):1264-1268, 2004. |
Gundy, et al., “Successful Thransplantation of Hearts Harvested 30 Minutes after Death from Exsanguination”, Ann. Thorac. Surg., 53(5):772-775, 1992. |
Habazetti, et al., “Improvement in Functional Recovery of the Isolated Guinea Pig Heart after Hyperkalemic Reperfusion with Adenosine”, J. Thorac. Cardiovasc. Surg., 111(1):74-84, 1996. |
Hachida, et al., “Abstract: Efficacy of Myocardial Preservation using HTK Solution in Continuous 120 Min Cross-Clamping Method—a Comparative Study with GIK Method”, Nippon Kyobu Geka Gakkai Zasshi, 41(9):1495-1501, 1993. |
Hardesty et al. Original Communications, “Autoperfusion of the heart and lungs for preservation during distant procurement,” J. Thorac. Cardiovasc. Surg., 93:11-18 (1987) (8 pages). |
Hartman, “The Role of Bradykinin and Nitric Oxide in the Cardiopulmonary Bypass and Hypothermic Circulatory Arrest in Piglets”, J. Card. Surg., 10:407-417, 1995. |
Hassanein, et al., “Continuous Perfusion of Donor Hearts in the Beating State Extends Preservation Time and Improves Recovery of Function”, The Journal of Thoracic and Cardiovascular Surgery, 116:821-830, 1998. |
Hassanein, Waleed et al: “A novel approach for 12 hour donor heart preservation.” Cardio-Thoracic and Vascular Surgery: Transplantation and Ventricular Assistance, Abstract 2080, 70th Scientific Session Cardio-Thoracic and Vascular Surgery: Transplantation and Ventricular Assistance, Circulation 96(8):I-372, 1997, 1 page. |
Heil, et al., “A Controlled Comparison of Kidney Preservation by Two Methods: Machine Perfusion and Cold Storage”, Transplant. Proc., 19(1):2046, 1987. |
Hülsmann et al. “Loss of cardiac contractility and severe morphologic changes by acutely lowering the pH of the perfusion medium: protection by fatty acids,” BBAGEN 20256, Biochimica et Biophysica Acta., 1033:214-218 (1990) (5 pages). |
Imber, et al., “Advantages of Normothermic Perfusion Over Cold Storage in Liver Preservation”, Transplantation, 73(5):701-709, 2002. |
International Search Report and Written Opinion for International Application No. PCT/US12/33626 dated Sep. 20, 2012. 13 pages. |
International Search Report for PCT/US07009652 dated Apr. 18, 2008. |
Janssen, et al., “UW is Superior to Celsior an dHTK in the Protection of Human Liver Endothelial Cells Against Preservation Injury”, Liver Transpl., 10(12):1514-1523, 2004. |
Katz, Robert et al. “Physics, CHapter 9: Hydrodynamics (Fluids in Motion).” Hydrodynamics. University of Nebraska—Lincoln. Pap143. No Month Listed 1958. 18 pages. |
Kawamura, et al., “Long-Term Preservation of Canine Pancreas by a New Simple Cold Storage Method using Perfluorochemical—The Two-Layer Cold Storage Method (Euro-Collins' Solution/Perfluorochemical)”, Kobe J. Med. Sci., 38(2):135-145, 1992. |
Kelly, “Current Strategies in Lung Preservation”, J. Lab. Clin. Med., 136:427-440, 2000. |
Keshavjee, et al., “A Method for Safe Twelve-Hour Pulmonary Preservation”, J. Thorac Cardiovasc Surg, 96:529-534, 1989. |
Kioka, et al., “Twenty-Four-Hour Isolated Heart Preservation by Perfusion Method with Oxygenated Solution Containing Perfluorochemicals and Albumin”, J. Heart Transplant, 5:437-443, 1986. |
Klatz, Richard: “Machine keeps human kidney alive for 24-hours.” The World Health Network Anti-Aging and Longevity (Aug. 25, 2001) (http://www.worldhealth.net/p/393,1313.htm). |
Kozaki, et al., “Usefulness of a Combination of Machine Perfusion and Pentoxifylline for Porcine Liver Transplantation from Non-Heart-Beating Donors with Prolonged Hypotension”, Transplant Proc., 29:3476-3477, 1997. |
Kuroda, et al., “A New, Simple Method for Cold Storage of the Pancreas Using Perfluorochemical”, Transplantation, 46(3):457-460, 1988. |
Lasley, et al,, “Protective Effects of Adenosine in the Reversibly Injured Heart”, Ann. Thorac. Surg., 60(3):843-846, 1995. |
Lawrence, Curtis: “Machine Preserves Organs Outside Body.” Chicago Sun-Times Health Section Online (Nov. 4, 2001) (no url listed), 1 page. |
Lefer, et al., “Attenuation of Myocardial Ischemia-Reperfusion Injury with Nitric Oxide Replacement Therapy”, Ann. Thorac. Surg., 60(3):789-792, 1995. |
Li, et al., “Functional Recovery in Rabbit Heart after Preservation with a Blood Cardiplegic Solution and Perfusion”, J. Heart Lung Transplant, 12(2):263-270, 1993. |
Li, et al., “Insulin in University of Wisconsin Solution Exacerbates the Ischemic Injury and Decreases the Graft Survival Rate in Rat Liver Transplantation”, Transplantation, 76(1):44-49, Jul. 15, 2003. |
Li, et al., “Insulin in UW Solution Exacerbates Hepatic Ischemia/Reperfusion Injury by Energy Depletion Through the IRS-2/SREBP-1C Pathway”, Liver Transpl., 10(9):1173-1182, 2004. |
Liu, et al., “Annexin V Assay-Proven Aitn-Apoptotic Effect of Ascorbic Acid 2-glucoside after Cold Ischemia/Reperfusion Injury in Rat Liver Transplantation”, Acta Med. Okayama, 57(5):209-216, 2003. |
Macchiarini, P. et al. “Ex vivo lung model of pig-to-human hyperacute xenograft rejection,” J. of Thoracic and Cardiovascular Surgery, 114:3, 315-325 (2000). |
Mankad, et al., “Endothelial Dysfunction Caused by University of Wisconsin Preservation Solution in the Rat Heart”, J. Thorac. Cardiovasc. Surg., 104(6):1618-1624, 1992. |
Matsuno, et al., “Effectiveness of Machine Perfusion Preservation as a Viablility Determination Method for Kidneys Procured from Non-Heart-Beating Donors”, Transplant. Proc., 26(4):2421-2422, 1994. |
Matsuno, et al., “The Effect of Machine Perfusion Preservation versus Cold Storage on teh Function of Kidneys from Non-Heart-Beating Donors”, Transplantation, 57(2):293-294, 1994. |
Menasche, “The Inflammatory Response to Cardiopulmonary Bypass and its Impact on Postoperative Myocaridal Function”, Curr. Opin. Cardiology, 10:597-604, 1995. |
Menasche, et al., “Experimental Evaluation of Celsior, a New Heart Preservation Solution”, Eur. J. Cardiothor. Surg., 8:207-213, 1989. |
Menasche, et al., “Improved Recovery of Heart Transplants with a Specific Kit of Preservation Solutions”, J. THorac. Cardiovasc., Surg., 105(2):353-363, 1993. |
Moller-Pedersen, et al., “Evaluation of Potential Organ Culture Media for Eye Banking Using Human Donor Corneas”, Br. J. Opthamol., 85(9):1075-1079, 2001. |
Morimoto, et al., “A Simple Method for Extended Heart-Lung Preservation by Autoperfusion”, Trans. Am. Soc. Aftif. Intern Organs, 30:320-324, 1984. |
Nicholson, et al., “A Comparison of Renal Preservation by Cold Storage and Machine Perfusion Using a Porcine Autotransplant Model”, Transplantation, 78(3):333-337, 2004. |
No Author Listed, “Human Heart Beats on its Own Outside Body”, USA Today, Oct. 6, 2001, 1 page. |
No Author Listed, “Human Heart Kept Alive Outside Body for First Time in Study of Portable Organ Preservation System at University of Pittsburgh Medical Center”, McGowan Institute for Regenerative Medicine, 2001, 2 pages. |
No Author Listed, “Machine Keeps Human Kidney Alive for 24-Hours”, reported by www.ap.org, Aug. 25, 2001, accessed via http://www.worldhealth.net/p/393.1313.html, date accessed Jul. 5, 2006, 1 page. |
No Author Listed, “Machine May be Organ Transplant Breakthrough”, USA Today, Aug. 25, 2001, 1 page. |
No Author Listed. “Custodiol HTK.” Physicians' Desk Reference. 57th Edition, Thomson PDR. ISBN:1-56363-445-7. No Month Listed—2003. 3 pages. |
No Author Listed. “SOLTRAN Kidney Perfusion Fluid.” Baxter. No Month Listed—2001-2004. 1 page. |
No Author Listed. “UW Solution Composition.” Date Unknown. 1 page. |
No Author Listed: “Human heart kept alive outside body for first time in Study of Portable Organ Preservation System at University of Pittsburgh Medical Center.” (Oct. 7, 2001) (http://www.upmc.com/Communications/MediaRelations/NewsReleaseArchives/By+/T/Transplantation/Pops.htm). |
No Author Listed, “New discovery in organ transplantation.” MSNBC Chicago (2001) (www.nbc5.com), 1 page. |
Odagiri, et al., “New Pulsatile Pump Using Assist Device—Hemodynamic Comparison of Pulsatile V-A Bypass (VABP), Pulsatile Left Heart Bypass (LHBP) and Constant Flow Left Heart Bypass (LHB)”, Journal of Japan Surgical Society, 83(6):515-523, Jun. 1982, English Abstract Only, 12 pages. |
Opelz, et al., “Comparative Analysis of Kidney Preservation Methods. Collaborative Transplant Study”, Transplant Proc., 28(1):87-90, 1996. |
Opetz, et al., “Advantage of Cold Storage over Machine Perfusion for Preservation of Cadaver Kidneys”, Transplantation, 33(1):64-68, 1982. |
Ota, et al., “Artificial Organ—Current State and Future of Substitution of Functions”, pp. 150-151, No Month Listed, 1983, 7 pages—English translation. |
PCT/US08/61454 International search report dated Dec. 5, 2008 (2 pages). |
PCT/US09/032619 International Search report, dated Jun. 4, 2009 (4 pages). |
PCT/US98/19912 International search report dated May 3, 1999 (4 pages). |
Pearl, et al., “Loss of Endothelium-Dependent Vasodilation and Nitric Oxide Release after Myocardial Protection with University of Wisconsin Solution”, J. Thorac. Cardiovasc., Surg., 107(1):257-264, 1994. |
Petrovsky, et al., “Justification and Application of a New Method for Transorganic Oxygen Preservation of the Kidneys”, Vestn Akad Med Nauk SSSR, 2:69-82, 1989. |
Pinsky, et al., “Restoration of the cAMP Second Messenger Pathway Enhances Cardiac Preservation for Transplantation in a Heterotopic Rat Model”, J. Clin. Invest., 92(6):2944-3002, 1993. |
Ploeg, et al., “Successful 72-Hour Cold Storage of Dog Kidneys with UW Solution”, Transplantation, 46(2):191-196, 1988. |
Pokorny, et al., “Histidine-Tryptophan-Ketoglutarate Solution for Organ Preservation in Human Liver Transplantation—a Prospective Multi-Center Observation Study”, Translp Int., 17(5):256-260, 2004. |
Potdar, et al., “Initial Experience Using Histidine-Tryptophan-Ketoglutarate Solution in Clinical Pancreas Transplantation”, Clin. Transplant., 18(6):661-665, 2004. |
Pozniak, Alexa: “Keeping Hearts Alive, Doctors Develop a High-Tech System to Salvage Donated Organs.” Boston ABCNews.com (Dec. 7, 2001) (http://abcnews.go.com/print?id=117085). |
Probst et al. “Carbohydrate and fatty acid metabolism of cultured adult cardiac myocytes,” Am. J. Physiol. 250 (Heart, Circ. Physiol. 19):H853-H860 (1986) (8 pages). |
Rao, et al., “Donor Blood Perfusion Improves Myocardial Recovery After Heart Transplantation”, J. Heart Lung Transplant., 16(6):667-673, 1997. |
Reddy, et al., “Preservation of Porcine Non-Heart Beating Donor Livers by Sequential Cold Storage and Warm Perfusion”, Transplantation, 77(9):1328-1332, 2004. |
Richens, et al., “Clinical Study of Crystalloid Cardioplegia vs Aspartate-Enriched Cardioplegia Plus Warms Reperfusion for Donor Heart Preservation”, Transplant. Proc., 24(1):1608-1610, 1993. |
Rinder, et al., “Blockade of C5a and C5b-9 Generatin Inhibits Leukocyte and Platelet Activation during Extracorporeal Circulation”, J. Clin. Invest., 96:1564-1572, Sep. 1995. |
Rosenkranz, et al., “Substrate Enhancement of Cardioplegic Solution: Experimental Studies and Clinical Evaluation”, Ann. THorac. Surg., 60:797-800, 1995. |
Rossi, Lisa: “New organ preservation solution easier to use.” Innovations Report (Feb. 2, 2003) (http://www.innovations-report.com/html/reports/medicine_report-18854.html). |
S.A.S.; “Investigations: Warm storage for donor organs.” The University of Chicago Magazine Online (2001) (no url listed), 1 page. |
Sangstat, the Transplant Company: “Celsior, Cold Storage Solution.” Sangstat Medical Corporation and Fresenius Kabi France. Aug. 1999, 5 pages. |
Sato, et al., “Supplemental L-Arginine During Cardioplegic Arrest and Reperfusion Avoids Regional Postischemic Injury”, J. Thorac. Cardiovasc. Surg., 110(2):302-314, 1995. |
Schimokawa, et al., “A New Lung Preservation Method of Topical Cooling by Ambient Cold Air Combined with High-Frequency Oscilation: An Experimental Study”, Transplant. Proc., 26(4):2364-2366, 1994. |
Schmid, et al., “Th eUse of Myocytes as a Model for Developing Successful Heart Preservation Solutions”, Transplantation, 52(1):20-26, Jul. 1991. |
Schon, et al., “Liver Transplantation after Organ Preservation with Normothemic Extracorporeal Perfusion”, Ann. Surg., 233(1):114-123, 2001. |
Schwalb, et al., “New Solution for Prolonged Myocardial Preservation for Transplantation”, J. Heart Lung Transplant., 17(2):222-229, 1998. |
No Author Listed, “2002 Design & Engineering Awards: Portable organ preservation system. TransMedics, Inc.”, Science, (2002), 1 page. |
Seccombe, et al., “Coronary Artery Endothelial Function After Myocardial Ischemia and Reperfusion”, Ann. Thorac. Cardiovasc. Surg., 60(2):778-788, 1995. |
Segal, et al., “Posttransplantation Function of Hearts Preserved with Fluorochemical Emulsion”, J. Heart Lung Transplant., 13(4):669-680, 1994. |
Segel, et al., “Recovery of Sheep Hearts after Perfusion Preservation in Static Storage with Crystalloid Media”, The Journal of Heart and Lung Transplantation, 17:211-221, 1998. |
Shirakura, et al., “Multiorgan Procurement from Non-Heart-Beating Donors by use of Osaka Universkty Cocktail, Osaka Rinse Solution, and the Portagle Cardiopulmonary Bypass Machine”, Transplant. Proc., 25(6):3093-3094, 1993. |
Southard, Dr. James: “The Right Solution for Organ Preservation.” Business Briefing: Global Surgery, Department of Surgery, University of Wisconsin, pp. 79-84, 2004, 6 pages. |
Steen, et al., “Transplantation of Lungs from Non-Heart-Beating Donors after Functional Assessment Ex Vivo”, Annals of Thoracic Surgery, 76:244-252, 2003, 11 pages. |
Stubenitsky, et al., “Kidney Preservation in the Next Millenium”, Transpl Int., 12:83-91, 1999. |
Sunamori, et al., “Relative Advantages of Nondepolarizing Solution to Depolarizing University of Wisconsin Solution in Donor Heart Preservation”, Transplant. Proc., 25(1):1613-1617, 1993. |
Tang, et al., “Warm Ischemia Lung Protection with Pinacidil: an ATP Regulated Potassium Channel Opener”, Ann Thorac Surg, 76:385-389, 2003. |
Tesi, et al., “Pulsatile Kidney Perfusion for Preservation and Evaluation: Use of High-Risk Kidney Donors to Expand the Donor Pool”, Transplant Proc., 25(6):3099-3100, 1993. |
The Associated Press: “Human heart beats on its own outside body.” (Oct. 6, 2001) (http://www.usatoday.com/news/health/2001-10-06-heart.htm). |
The University of Wisconsin Board of Regents: “Formula for Belzer MPS Solution.” The University of Wisconsin (Oct. 3, 2003) (http://www.surgery.wisc.edu/transplant/research/southard/BelzerMPS.shtml). |
Turpin, et al., “Perfusion of Isolated Rat Adipose Cells,” The Journal of Clinical Investigation, 60:442-448 (1977), 7 pages. |
ViaSpan (Belzer UW) Cold Storage Solution, Data Sheet, Barr Laboratories, Inc., May 2002, 2 pages. |
Vinten-Johnsen, et al., Reduction in Surgical Ischemic-Reperfusion Injury with Adenosine and Nitric Oxide Therapy, Ann. Thorac. Surg., 60(3):852-857, 1995. |
Voiglio, E. et al. “Rat multiple organ blocks: microsurgical technique of removal for ex vivo aerobic organ preservation using a fluorcarbon emulsion,” Microsurgery 20:3, 109-115 (2000). |
Watanabe, et al., “Effects of Free Fatty Acids on the Binding of Bovine and Human Serum Albumin with Steroid Hormones”, Biochimica et Biophysica Acta (BBA), 1289:385-396, 1996. |
Wicomb, et al., “24-Hour Rabbit Heart Storage with UW Solution”, Transplantation, 48(1):6-9, 1989. |
Wicomb, et al., “Cardiac Transplantation Following Storage of the Donor Heart by a Portable Hypothermic Perfusion System”, The Annals of Thoracic Surgery, 37(3):243-248, 1984. |
Wicomb, et al., “Orthotopic Transplantation of the Babook Heart After 20 to 24 Hours Preservation by Continuous Hypothermic Perfusion with an Oxygenated Hyperosmolar Solution”, The Journal of Thoracic and Cardiovascular Surgery, 83(1):133-140, 1982. |
Wright, N. et al. “A porcine ex vivo paracorporeal model of lung transplantation,” Laboratory Animals, 34:1, 56-62 (2000). |
Yland, et al., “New Pulsatile Perfusion Method for Non-Heart-Beating Cadaveric Donor Organs: A Preliminary Report”, Transplantation Proceedings, 25(6):3087-3090, 1993. |
Zhang, et al., “Research Progress on Preservation of Severed Limbs”, Chinese JOurnal of Reparative and Reconstructive Surgery, 14(3):189-192, 2000. |
Zhengquang, et al., “A Study on the Preservation of Rat Kidney with HX-III Solution”, WCUMS 31(3):347-349, 2000. |
Carrier, B., “Chapter 4: Hypoxia and Oxygenation”, Alaska Air Medical Escort Training Manual, Fourth Edition, pp. 71-82, 2006, 12 pages. |
Definition of Examine, Merriam-Webster Dictionary on-line. www.merriam-webster.com/dictionary/examine, Printed Feb. 9, 2011, (1 page). |
Egan, T. M. et al., “Ex Vivo Evaluation of Human Lungs for Transplant Suitability”, Ann Thorac Surg, vol. 81, No. 4, pp. 1205-1213 (Apr. 2006) (9 pages). |
Synchrony Definition, http://dictionary.reference.com/browse/synchrony, Random House Unabridged Dictionary, 2006 (1 page). |
Yeung, J. C., et al., “Physiologic assessment of the ex vivo donor lung for transplantation”, The Journal of Heart and Lung Transplantation, 31(10):1120-1126, Oct. 2012 (7 pages). |
Chinchoy, Edward Cheng-wey; “The Development, Refinement, and Uses of a Physiologically Working Isolated Ex Vivo Swine Heart Model”, A thesis submitted to the Faculty of the Graduate School of the University of Minnesota, Dec. 1999 (136 pages). |
Johnson, Kerry et al, “POPS: Portable Organ Preservation System”, UPMC Health System and TransMedics, Inc. (No date given) (1 page). |
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “Drugs@FDA-Solu-Medrol: Label and Approval History”, (Available online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist . . . ), accessed Feb. 9, 2010 (3 pages). |
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “Drugs@FDA-Solu-Medrol: Drug Details”, (Accessible online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails . . . ), accessed Feb. 9, 2010 (1 page). |
Kubono, K. et al., “Examination of Plasma and Corpuscle Adenosine Concentration in Normal Subject by Radioimmunoassay”, Rinshou Kagaku (Clinical Chemistry, 20(2):72-77, Jun. 1991 (6 pages)—Japanese Language. |
Sekine, M. et al., “Effect of Obese and Aging on Blood Fatty Acid Consumption in Japanese”, Bulletin of the Graduate School of Human Life Science, Showa Women's University, 4:63-70, 1995 (8 pages)—English Abstract. |
Yokoyama, H. et al., “Isolated Dog Hearts Prepared in Cold Tyrode Solution and Reperfused with Arterial Blood Are Functionally and Ultrastructurally Normal”, The Tohoku Journal of Experimental Medicine, 156:121-134, 1988 (14 pages). |
International Search Report and Written Opinion issued by the U.S. Patent and Trademark Office as Searching Authority, in International Application No. PCT/US16/50512, dated Dec. 12, 2016 (9 pages). |
Extended European Search Report issued in European Application No. 17172411.5, dated Nov. 8, 2017 (7 pages). |
Number | Date | Country | |
---|---|---|---|
20150342176 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
60725168 | Oct 2005 | US | |
60694971 | Jun 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11246919 | Oct 2005 | US |
Child | 14734769 | US |